A B S T R A C T In 66 untreated patients with hyperthyroidism, serum triiodothyronine (Ts) and thyroxine (T4) concentrations were measured by immunoassay.
serum T4/Ts ratio by weight was 48±2 as opposed to a value of 71±3 in euthyroid adults. There was a significant inverse correlation of the T4/Ts ratios with serum T3 (r 0.77; P<0.01) but not with serum T4 (r 0.21). These results suggested that relative overproduction of Ts is consistently present in patients with hyperthyroidism.
To examine the acute effects of various antithyroid agents on serum Ts and T4 concentrations, iodide, propylthiouracil (PTU), and methylmercaptoimidazole (MMI) were given alone to nine patients, and serial Ts and T4 measurements were made. There was an acute decrease in serum Ts over the first 5 days in the three iodide and three PTU-treated patients which was greater than that seen in the MMI group. This suggested that PTU and MMI had different effects on Ts production.
To compare the effects of PTU and MMI under conditions in which thyroidal hormone release was minimized, these drugs were given in combination with iodide. The mean daily dosage of PTU was 827 (n = 11) and of MMI was 88 (n = 8). In the PTU + iodide group, the initial serum T8 concentration was 586±61 ng/100 ml and decreased significantly to 326±41 on day 1 and to 248+21 and 231+20 on days 2 and 3, respectively, and did not change further on days 4 and 5. In the MMI + iodide group, basal serum Ts was 645+90 ng/100 ml and decreased to 568+81, 452±73, and 344± 51 on days 1, 2, and 3, respectively, and did not change Previous investigations have shown that PTU inhibits T4 deiodination in hyperthyroid patients and decreases T3 production from T4 in animals. The greater acute decrease in serum T3 and the higher serum T4/Ts ratios in the PTU-treated patients seems best explained by an inhibition of peripheral Ts production by this agent. This conclusion is further supported by a direct relationship between the T4/T3 ratio on days 3-5 and the dose of PTU administered. These results further suggest that both thyroidal and extrathyroidal pathways contribute substantially to the apparent overproduction of T3 in hyperthyroidism.
INTRODUCTION
There is increasing evidence that triiodothyronine (Ts)' plays an important role in normal thyroid physiology.
It has even been speculated that thyroxine (T4) exerts 'Abbreviations used in this Paper: MMI, methylmercaptoimidazole; PTU, propylthiouracil; SSKI, saturated solution of potassium iodide; T3, triiodothyronine; T4, thyroxine.
little metabolic effect unless it is deiodinated to T8 in the peripheral tissues (1) . Although thyrotoxicosis is most commonly associated with increases in circulating levels of both To and Ts, review of the available studies indicates that the concentration of the latter is generally elevated to a greater extent than is To (2) . The mechanism of this disproportionate increase in Ts and its metabolic implications are not clearly understood. Since serum Ts elevations appear to be consistently present in hyperthyroid patients and since T3 may be the active form of thyroid hormone, it was of interest to document the changes in its concentration during therapy with commonly used antithyroid agents. In addition, the halflife of Ts is short so that inhibition of Ts production should be rapidly reflected in decreases in serum hormone concentrations. Preliminary studies from this laboratory have indicated that substantial changes in circulating Ts may occur within 24 h of initiation of therapy (3) . The studies reported below were performed to compare changes in Ts and To levels during the early time periods after starting treatment with propylthiouracil (PTU) or methylmercaptoimidazole (MMI) alone or in combination with iodide. 
METHODS
The patients employed in this study were clinically and chemically hyperthyroid. All were hospitalized at the University of Pittsburgh Health Center Hospitals. In 66 patients serum T3 and To concentrations were measured before treatment by radioimmunoassay techniques described previously (4, 5) . 28 patients with Graves' Disease were studied during therapy while inpatients either in the Clinical Research Unit or the medical wards of the PresbyterianUniversity Hospital or V. A. Hospital. These patients were given various drug regimens on a random basis. All drugs were administered orally every 6 or 8 h with one exception where NaI was administered intravenously. Collection of blood samples was performed at two different times before therapy and every 12-24-h after initiation of therapy and for 5 days in most cases. The samples were allowed to clot, and the serum was separated and frozen until assayed. Serial determinations of T3 and T4 were performed in duplicate, at two dilutions, in the same assay for each patient, and at least in two different assays. T4/Ts ratios were calculated on a weight basis. The study groups were as follows: alone. In Fig. 2 are shown results of preliminary studies performed to explore the quantitative changes in Ts and T4 in patients receiving these agents. With iodide therapy, there is an acute decrease in circulating Ts to 50% of the initial level by day 4. To values are also significantly lower on day 4, but the decrease is only to 70% of control levels. The mean T4/Ts ratio at 4 days was 58 compared to 42 initially. The more rapid decrease in serum Ts than in serum T4 was anticipated following inhibition of thyroidal secretion since the half-life of Ts is considerably shorter than T4. Therefore, the increase in the T4/Ti is consistent with an acute inhibition of thyroidal secretion which has been previously demonstrated to occur during iodide administration to hyperthyroid subjects (6, 7) . The failure of serum Ts to fall to normal levels is presumably a reflection of both incomplete inhibition of thyroidal release as well as persistence of Ts production from T4 in the periphery.
With MMI therapy the pattern of changes varies. In one patient there is an acute decrease in serum Ts to about 55% of the initial level by day 3 and an associated decrease in serum T. of less magnitude. In the other two patients, a slight decrease in T3 levels to about 70% of the initial level was seen in one, no change in Ts in the other, and neither showed significant changes in T4.
The heterogeneity of the response pattern of these patients to MMI is not surprising since this drug inhibits synthesis of thyroid hormones but has no effect on the release of previously formed hormonal stores. Since these may vary quantitatively in different individuals with hyperthyroidism, early changes in serum Ts and T4 concentrations during treatment with MMI would be expected to vary accordingly.
During treatment with PTU the decreases in serum Ta concentrations were more uniform. Mean serum Ts concentrations decreased significantly to 50% of the initial level on day 3. The decreases in serum T3 occurred in the absence of significant decreases in serum T4 and are reflected in marked acute increases in the T4/Ts ratios. The uniformity of the response to PTU and the magnitude of the decrease in serum Ts concentrations suggested an effect different from that of MMI.
Previous studies have indicated that PTU inhibits peripheral deiodination of To in hyperthyroid subjects (8, 9) . Since this effect of PTU is associated with inhibition of Ts production in animals, it seemed possible TX and T4. Acute Changes with Therapy that a similar mechanism could account for the acute decreases in serum T3 seen in these patients (10) . Therefore, we examined this possibility under conditions where the qualitative and quantitative contributions of secretion of preformed hormones was minimized by the concomitant administration of iodide. MMI, which has not been shown to have a peripheral effect in man, provided a control for the antithyroid effect of PTU (11, 12) .
Acute changes in serum Ti and T4 in hyperthyroid patients treated with PTU or MMI combined with iodide.
The effect of treatment of hyperthyroid patients with the combination of PTU or MMI with iodide is shown in Fig. 3 , and the individual data are presented in Table  I Comparison of the acute changes in the serum Ts/Ts ratios. The simultaneous changes in serum T3 and To resulted in marked acute increases in the Ti/Ta ratios in the patients receiving PTU + iodide (Fig. 4) value of 52±3 were all significantly lower than the values in the former group (P < 0.005 for day 1; P < 0.001 for day 2, and P < 0.001 for days 3-5). These results suggest that the larger acute decreases in serum T3 on days 1 and 2 during PTU + iodide therapy cannot be explained adequately either by inhibition of thyroid hormone secretion by iodide or by the antithyroid effect of PTU alone. The abrupt increase in the T4/Ta ratio suggests that there is inhibition of peripheral deiodination of T4.
Correlation of the "plateau" T4/Ts ratio and dose of antithyroid agent. If PTU inhibits peripheral T3 production, then a dose-response relationship might be anticipated between the amount of drug given and the T#/Ts ratio. As mentioned above, after the acute increases in the first 2 days, there was no significant change in these ratios in either group during days 3-5 (Fig. 4) . Therefore, it seemed reasonable to use the average value of T4/Ta during this period as an index of the maximum acute response of the individual patients to the antithyroid therapy. When the "plateau" T4/T3 ratios were plotted for each individual against the corresponding dosage, a significant direct correlation was observed between this ratio and the dose of PTU (Fig. 5) . This relationship was not apparent with MMI. A similar relationship is observed in PTU-treated patients when the percentage decrease in serum T3 on day 1 is plotted against the dose of PTU given (r = 0.78, P <0.01, not shown). Again, there was no such correlation in the patients receiving MMI. The results in the PTU-treated group could not be explained on the basis of higher initial serum Ts concentrations in the patients receiving larger doses of this drug since the initial T3 values in the groups receiving different doses of PTU were essentially the same. Specifically, the mean initial T3 concentrations were 504+47, 614+132, and 627±115 in patients receiving daily doses of 300-450 mg (three), 750 mg (four), and 900-1,600 mg (four), respectively (Table I) .
DISCUSSION
The significant inverse correlation of T4/T3 ratios with serum Ts concentrations in untreated hyperthyroidism indicates that greater increases in circulating T3 relative to T4 are consistently observed in this condition. This relative excess of T8 could be due either to relatively smaller increases in the metabolic clearance of T3 than in the metabolic clearance of T4 or to a disproportionate increase in the production rate of this hormone. Studies by Nicoloff, Low, Dussault, and Fisher in hyperthyroid subjects suggest that the former possibility is unlikely since parallel increases in the disappearance rates of both labeled Ts and T4 were observed in this condition (13) . The study further estimated that there was a 7-fold increase in the daily production of Ts whereas production of T4 was increased only 3.5-fold. The relative overproduction of T3 in turn could be a result of either increased thyroidal Ts secretion or increased quantities of Ts arising from peripheral deiodination of T4 or both. Review of recent studies by several laboratories suggests that this latter pathway is the major source of circulating T3 in euthyroid subjects (2) . If one assumes that the fraction of T4 which is converted to Ts per day remains constant in hyperthyroidism, then rough estimates of the relative contribution of the two pathways to the peripheral T3 pool can be made. While the precise proportion of the peripheral T3 pool deriving from T4 is a matter of debate, a recent review of the literature suggests that a minimum of about two-thirds comes from this source (2) . This would amount to about 80 ng/100 ml of the normal serum T3 concentration of about 120 ng/100 ml.
If peripheral T3 production were increased 3.5-fold as is total T4 production in hyperthyroidism (i.e., if the fractional T4 to Ts conversion remains constant) an increase to a serum T8 concentration of 280 ng/100 ml would be anticipated. This amounts to 46% (280/610) of the mean serum Ts level in 19 patients examined in detail in this study. These approximations would indicate that the thyroid and the periphery contribute about equally to the Ts pool in hyperthyroidism and that the acute inhibition of either pathway would cause similar initial decreases in serum Ts concentrations.
The observation that iodide alone caused a rapid fall in circulating T3 is evidence substantiating the acute inhibition of thyroid hormone secretion produced by this agent in hyperthyroid subjects. The acute inhibition of release of 'I from prelabeled glands was first demonstrated by Goldsmith and Eisele (14) using epithyroid counting techniques and more recently verified in studies by Wartofsky, Ransil, and Ingbar by analysis of the changes in stable and labeled serum T4 concentrations during iodide administration (7) . The latter reported a mean decrease of 74% in To secretion rate. Since the half-life of Ts is short relative to To, changes in the concentration of this hormone are more abrupt than changes in the latter. Since some decreases in T4 were present during iodide therapy, peripheral T3 production was presumably decreased as well and contributed to the overall changes observed. The effect of an agent such as MMI on T3 levels is more difficult to analyze. It is apparent that despite the presence of effective inhibition of T4 and Ts synthesis, release of these hormones will continue until the preformed stores are depleted. The duration of continued T3 and T4 secretion will be a function of the amount of colloid and the thyroidal release rate in each individual. Thus, a heterogeneous response might be expected in any group of hyperthyroid patients. This was observed in the three patients receiving MMI (Fig. 2) . A similar type of response would be anticipated in patients treated with PTU if its only mechanism of action was to inhibit thyroidal hormone production. However, in our preliminary studies, the decreases in serum T3 during therapy with PTU alone appeared to be both more acute and more consistent than those seen with MMI. This effect was different from that obtained with iodide alone in that simultaneous decreases in T4 concentration were minimal. Consequently, the increases in T#/Ta ratios were greater with PTU than with either MMI or iodide. The consistency of the response pattern during PTU therapy argued against the chance occurrence of low intrathyroidal pools of Ts relative to To in the patients treated with this drug. Alternatively, it suggested that perhaps the acute decrease in serum Ts in the absence of significant changes in serum T4 could result from inhibition of peripheral T3 production from T4.
The evidence that PTU inhibits deiodination of To in the experimental animal has been extensively reviewed by Morreale de Escobar and Escobar del Rey (15) . Recent studies by Oppenheimer, Schwartz, and Surks have further documented that PTU administration to rats results in a decrease in the generation of labeled Ts from labeled T4 (10) . Other studies have reported evidence of inhibition of T4 deiodination in hyperthyroid subjects (8, 16) . More recently, Nicoloff reported that PTU caused an acute inhibition of T. deiodination in euthyroid subjects (12) . This effect was not shared by either MMI or iodide.
To our knowledge, there are no previous studies of the effect of PTU-induced inhibition of T4 deiodination on peripheral Ts production in either hyperthyroid or euthyroid subjects. It was apparent from the preliminary studies that the comparison of the effects of MMI and PTU on peripheral Ts production in hyperthyroidism would be complicated by the previously discussed differences in thyroidal stores in different individuals. To overcome this problem, PTU and MMI were combined with iodide. Under these circumstances, the release of both thyroid hormones would be expected to be decreased to approximately 25% of the initial rate. Acute changes in circulating T3 would, then, better reflect primary effects on peripheral T8 production. The gradual decrease in circulating T3 observed in the patients receiving MMI + iodide did not appear substantially different from the effects of iodide alone in the preliminary studies. The serum Ts concentration appeared to plateau at about 340 ng/100 ml or 53% of the control level at about 3 days, consistent with the approximations outlined previously. The abrupt decrease of the serum T3 to 56% of control on day 1 and to 42% of control on day 2 in the PTU group indicates that both pathways for T3 production are inhibited. The decreasing T4 levels in both groups was presumably a result of the iodide therapy. While there was no significant difference in the serum T4 values between the two groups, this disappearance slope appeared shallower in the PTU-treated group as would be anticipated if T4 deiodination were inhibited. While circulating T, might then tend to be higher in this group, it was primarily the significant decreases in circulating T3 which resulted in the marked elevations in the serum T4/T8 ratio. Since the drugs were given in roughly the accepted potency ratio, namely, 10: 1 for PTU versus MMI, it is probable that the inhibition of thyroid hormone synthesis induced by these agents was also equivalent. Because of the substantial acute inhibition of thyroidal release rate produced by iodide, small differences in the inhibition of thyroid hormone synthesis in the two groups would play little role in the observed responses.
However, the concomitant administration of iodide and antithyroid drugs requires one further comment. If inhibition of thyroid hormone formation were incomplete with these amounts of PTU and MMI, then the additional amounts of iodide could lead to the synthesis of greater amounts of hormones than would be formed in the presence of the antithyroid drugs alone. Since PTU is perhaps less than 10% as potent as MMI by weight (17) , one could speculate that the T4/Ts ratio of newly synthesized hormones in PTU-treated patients would be greater than in MMI-treated patients, since greater restriction of iodine organification could result from the more efficient blockade by the latter drug.
The situation might be analogous to studies in rats where iodine deficiency results in a decrease in the T4/Ta ratio of synthesized hormones (18) . However, absolute T3 production during the apparent plateau period (days 3-5) appears to be about 50% greater during MMI therapy than during treatment with PTU. It thus seems difficult to explain the higher total T3 production rate in MMI-treated patients as due to a greater absolute rate of thyroidal Ts secretion resulting from more complete inhibition of organification. It is perhaps more likely, at least acutely, that the high iodide levels, in addition to inhibiting hormone release, also caused intracellular iodide concentrations sufficiently elevated to cause further inhibition of the organification process in both groups through the Wolff-Chaikoff effect (19) . The similarity of the pattern of response in the PTUtreated patients, whether or not added iodide was given, would add support to these theoretical arguments.
The previous studies in animals and man, as well as the present results, point to inhibition of T4 deiodination as the best explanation for the acute decreases in circulating Ti resulting from PTU therapy. Further support for this interpretation is found in the dose-response relationships between the "plateau" T4/Ts ratio (or the Ts decrement on day 1) and the dose of PTU administered (Fig. 5) . A similar dose-response relationship over a range of 100-1,000 mg was demonstrated for PTU inhibition of To deiodination in euthyroid subjects by Nicoloff (12) . Previous investigations suggest that the maximum inhibition of T4 deiodination by PTU in the rat is approximately 50% (15) . If there is a similar limit in man, a plateau in this curve should eventually occur which was not evident in our studies nor in the above mentioned studies in euthyroid subjects (12) .
Certain clinical implications of this study deserve further comment. If T3 is the active form of thyroid hormone and serum concentrations are an accurate reflection of the availability of this hormone to the cells, then the acute response of patients to treatment with PTU + iodide is clearly superior to the results with MMI + iodide. Whether the chemical improvements will be paralleled by more rapid clinical improvement is currently under investigation. Unfortunately, the present series of patients was not objectively evaluated from a clinical standpoint. However, these results are sufficiently impressive to make PTU (as opposed to MMI) in combination with iodide, our drug-of-choice in the treatment of patients with thyroid storm. In patients with less severe manifestations of thyrotoxicosis, the potential benefits of more rapid decreases in T3 levels with PTU + iodide (or MMI + iodide) must be weighed against the risks of giving two drugs simultaneously. The peripheral effects of PTU might also be therapeutically advantageous in the treatment of exogenous thyroxine in-toxication or in postsurgical or '3.I therapy-induced thyroid storm where minimal effects of any agents on thyroid hormone release are anticipated. In addition, the present studies are acute and may, therefore, have limited applicability to the effects of chronic PTU or MMI therapy on circulating Ts and T4 concentrations.
